Breast cancer survivors who experience hot flashes as a result of their treatment now have a new option to alleviate their symptoms.
The U.S. Food and Drug Administration (FDA) has recently approved Veozah, a hormone-free drug that targets the brain's temperature control center to reduce both the frequency and intensity of hot flashes.
Hot flashes are a common side effect of breast cancer treatment, and they can significantly impact a woman's quality of life.
Prior to the approval of Veozah, the main treatment options for hot flashes related to breast cancer were hormone replacement therapy (HRT) and some types of antidepressants. However, these treatments are not always suitable for breast cancer survivors due to their potential risks and side effects.
The introduction of Veozah is a significant breakthrough for breast cancer survivors who have been struggling with hot flashes. This new drug provides an additional safe and effective treatment option that can help alleviate their symptoms without compromising their health.
Veozah - A Game Changer for Breast Cancer Survivors
According to ABC, Veozah is the first drug of its kind to be approved by the FDA to treat moderate to severe hot flashes in menopausal women, including breast cancer survivors.
It is hormone-free, making it a promising option for women who cannot take hormone treatment due to other underlying health concerns.
Veozah, the newly FDA-approved drug, functions by specifically targeting the part of the brain responsible for regulating body temperature.
This mechanism results in a decrease in the occurrence and severity of hot flashes experienced by women.
Breast cancer treatment can trigger early menopause, leading to a range of symptoms, including hot flashes.
Studies have shown that up to 70% of women with breast cancer experience hot flashes, which can significantly impact their quality of life.
The approval of Veozah offers a new ray of hope for breast cancer survivors who have been struggling with this debilitating symptom.
How Veozah Works
Veozah works by selectively blocking the action of a particular protein that is involved in regulating body temperature.
Based on the FDA, this protein, called neurokinin-3 receptor (NK3R), is found in the hypothalamus, a region of the brain that controls body temperature. By blocking the NK3R, Veozah helps to regulate body temperature and reduce the frequency and intensity of hot flashes.
In clinical trials, Veozah has been shown to be safe and effective in reducing hot flashes in menopausal women, including breast cancer survivors.
The drug is taken orally once a day, making it a convenient and easy-to-use option for women.
A New Hope for Breast Cancer Survivors
Breast cancer survivors who experience hot flashes have been eagerly awaiting a new treatment option that is safe, effective, and hormone-free.
The approval of Veozah by the FDA offers a new hope for these women, who have been struggling with the debilitating symptoms of menopause.
According to NBC, Veozah represents a significant breakthrough in the treatment of hot flashes, not just for breast cancer survivors, but for all women experiencing menopause.
This new drug provides a safe and effective alternative to hormone therapy and antidepressants, offering women a new choice in managing their symptoms.
In conclusion, the approval of Veozah by the FDA is a significant milestone in the treatment of hot flashes, particularly for breast cancer survivors.
This new drug provides a safe and effective option for women who have been struggling with the debilitating symptoms of menopause.
With the introduction of Veozah, breast cancer survivors can now look forward to a better quality of life, free from the burden of hot flashes.
